{"entity":{"id":"nct07669519","kind":"trial","name":"Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy","aka":[],"tldr":"A phase 3 trial of Nuvastatic™ in colorectal cancer, run by Natureceuticals Sdn Bhd, now recruiting.","summary":"Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy is a phase 3 interventional study registered as NCT07669519 by Natureceuticals Sdn Bhd, with 180 participants planned, started 2025-08-18 and due to reach its primary completion in 2027-03-31. Interventions recorded: Nuvastatic™ and Placebo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07669519","url":"https://clinicaltrials.gov/study/NCT07669519"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07669519","phase":"3","setting":"Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy","sponsor":"Natureceuticals Sdn Bhd","enrolled":180,"outcomes":[]},"route":"/trials/nct07669519/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}]}}